111 Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
111 Capital's NBIX Position: Q2 2026 in Review
111 Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,628 shares worth $443K. The stake represents 0.08% of the portfolio and ranks #262 among its holdings. This is a return to the name: 111 Capital previously reported a position in NBIX as recently as Q3 2025.
111 Capital first reported a position in NBIX in Q3 2025 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- 111 Capital held 2,628 shares of Neurocrine Biosciences worth $443K as of Q2 2026.
- Neurocrine Biosciences was a new 111 Capital position in Q2 2026.
- Neurocrine Biosciences made up 0.08% of 111 Capital's portfolio in Q2 2026, its #262 holding.
- 111 Capital first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 2 quarters since.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.